ImmuneOncia: A PD-L1 Latecomer Hoping To Break Into The Market
Executive Summary
Emerging Company Profile: ImmuneOncia may be late entering the market for PD-L1 inhibitors, but the joint venture between Yuhan and Sorrento Therapeutics aims to develop best-in-class immuno-oncology drugs with differentiated products and strategy.
You may also be interested in...
Finance Watch: Seed/Series A Financings Benefit As Big Crossover Rounds Slow
Silicon Valley Bank data show a pullback in crossover financings but an increase in seed and series A venture capital rounds. In recent private company financings, CRO Novotech raised $760m. In public company financings, Eleusis will merge with a SPAC and the Bausch + Lomb IPO is on file with the SEC.
Asia Deal Watch: Vibegron’s Vagabond Journey Continues With Eisai Acquiring Partial Asian Rights
Kyorin, Eisai build on earlier OAB deal to team on vibegron. Plus deals involving Piramal/Hemmo, ImmuneOncia/3D Medicines, Kyowa Kirin/Cerecor, Simcere/Kazia, Nippon Shinyaku/Menarini, Tarsus/LianBio
Korean Pharma Finds Own Way To Collaborative And Open Innovation
Taking into consideration global and domestic trends, South Korean pharmas are increasingly finding their own strategies to seek open innovation and collaborations to develop novel new drugs. Two leading firms from the country shared their know-how and showcased successful open innovation cases during a recent gathering organized by a national industry association.